Journal: Cell reports. Medicine
Article Title: Clinical-proteomic classification and precision treatment strategy of chordoma.
doi: 10.1016/j.xcrm.2024.101757
Figure Lengend Snippet: Figure 6. Precision treatment strategy for chordoma subtypes (A) The correlation between chordoma cell lines and the identified three clusters. (B) Tumor volumes of denosumab- and PBS-treated PDX model (cluster 1, SA47). (C) IC50 of S-Gboxin for CH22 cells. MTT assay (D), clone formation assay (E), and OCR (F) of CH22 cells after the treatment of S-Gboxin. (G) Tumor volumes of S-Gboxin- and PBS-treated PDX model (cluster 2, SA20). (H) Tumor volumes of S-Gboxin- and PBS-treated CH22-bearing nude mice. (I) IC50 of anlotinib for U-CH2 cells. MTT assay (J) and clone formation assay (K) of U-CH2 cells after the treatment of anlotinib. (L) Tumor volumes of anlotinib- and PBS-treated PDX model (cluster 3, SA50). (M) Tumor volumes of anlotinib- and PBS-treated U-CH2-bearing nude mice. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: IC50, inhibitory concentration 50; PDX, patient-derived xenograft; PBS, phosphate buffer saline; OCR, oxygen consumption rate.
Article Snippet: Cells were exposed to various concentrations of Denosumab (Selleckchem), Anlotinib (Selleckchem) or S-Gboxin (Selleckchem) for respective time points as indicated.
Techniques: MTT Assay, Tube Formation Assay, Concentration Assay, Derivative Assay, Saline